The natural HLA-Peptidome of Sezary Syndrome: uncovering antigens for T cell-based immunotherapy

Lydon Nyambura; Kathrin Textoris-Taube; Peter Walden

doi:10.20883/medical.e1335

Authors

Lydon Nyambura Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany https://orcid.org/0000-0003-2197-6048
Kathrin Textoris-Taube Core Facility – High-Throughput Mass Spectrometry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility – High-Throughput Mass Spectrometry, Berlin, Germany https://orcid.org/0000-0002-1224-8236
Peter Walden Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany https://orcid.org/0000-0002-8986-3667

DOI:

https://doi.org/10.20883/medical.e1335

Keywords:

Sezary syndrome, HLA-I peptides, LC-MS/MS, immunopeptidome, immunogenicity

Abstract

Introduction. Sezary syndrome (SS) is a rare and aggressive form of cutaneous T-cell lymphoma, that has a poor prognosis, with a median overall survival time of less than 3 years. Despite advances in its treatment, SS is a challenge to manage, often characterized by high rates of relapse and limited response to therapy in many patients. The main challenge for treatment, including vaccine development is its heterogeneity. In its molecular and genetic characteristics, clinical presentation, disease progression, and treatment response. Understanding the SS heterogeneity at the omics level is vital in developing T-cell mediated immunotherapeutic.

Material and methods. In this study naturally presented human leukocyte antigen class I (HLA-I) peptides were isolated from SS patients leukophoresis samples and analyzed using high performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), and source proteins evaluated for immunotherapy application.

Results. The total number of HLA-I–restricted peptides and source proteins identified in SS leukophoresis patient samples was about the same, and they were heterogeneous and individualized. Only a small fraction of HLA-I peptides and source proteins was found to be shared between and among the patients. Peptide lengths were dominated by nanopeptides, with preferred processing by chymotrypsin. The source proteins were predominantly from the cytoplasm, and primarily involved in biosynthesis and regulation. Furthermore, the HLA-I peptides were presented from proteins of top 20 genes with somatic mutations in SS that include NCOR1, TRRAP, JAK3, PLCG1, TP53 and STAT3 (SS associated antigens - SAAs). These SAAs had varying mutation types and frequencies- dominated by missense variant, allele-dependent immunogenicity- highest in HLA-A*11:01 and HLA-A*02:01 and lowest for HLA-A*01:01-with TRRAP showing high affinity peptides, low gene expression levels in normal tissue (except STAT3), significant protein interaction network- including JAK3 and STAT3 at primary level.

Conclusions. This study findings, contributes to the overall understanding SS HLA-I peptidome landscape, and highlights potential T-cell mediated immunotherapeutic targets.

Downloads

Download data is not yet available.

References

Alaggio R, Amador C. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–48. https://doi.org/10.1038/s41375-022-01620-2

Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–14. https://doi.org/10.1182/blood-2018-11-881268

Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730–9. https://doi.org/10.1200/jco.2009.27.7665

Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015;33:3766–73. https://doi.org/10.1200/jco.2015.61.7142

Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70:223.e1-17; quiz 240–2. https://doi.org/10.1016/j.jaad.2013.08.033

Querfeld C, Zain J, Rosen ST. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome. Cancer Treat Res. 2019;176:225–48. https://doi.org/10.1007/978-3-319-99716-2_11

Stuver R, Geller S. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments. Front Immunol. 2023;14:1284045. https://doi.org/10.3389/fimmu.2023.1284045

Roccuzzo G, Giordano S, Fava P, Pileri A, Guglielmo A, Tonella L, et al. Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. Front Oncol. 2021;11:733770. https://doi.org/10.3389/fonc.2021.733770

Larocca C, Kupper T. Mycosis Fungoides and Sézary Syndrome: An Update. Hematol Oncol Clin North Am. 2019;33:103–20. https://doi.org/10.1016/j.hoc.2018.09.001

Buus TB, Willerslev-Olsen A. Single-cell heterogeneity in Sézary syndrome. Blood Advances. 2018;2:2115–26. https://doi.org/10.1182/bloodadvances.2018022608

Litvinov IV, Tetzlaff MT, Thibault P, Gangar P, Moreau L, Watters AK, et al. Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. Oncoimmunology. 2017;6:e1306618. https://doi.org/10.1080/2162402x.2017.1306618

Vergnolle I, Douat-Beyries C, Boulinguez S, Rieu JB. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome. Blood Advances. 2022;6:1813–25. https://doi.org/10.1182/bloodadvances.2021005147

Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016;7:13404. https://doi.org/10.1038/ncomms13404

Caron E, Kowalewski DJ, Chiek Koh C, Sturm T, Schuster H, Aebersold R. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. Mol Cell Proteomics. 2015;14:3105–17. https://doi.org/10.1074/mcp.O115.052431

Hellinger R, Sigurdsson A. Peptidomics. Nature Reviews Methods Primers. 2023;3.25 https://doi.org/10.1038/s43586-023-00205-2

Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget. 2016;7:5110–7. https://doi.org/10.18632/oncotarget.6960

Shapiro IE, Bassani-Sternberg M. The impact of immunopeptidomics: From basic research to clinical implementation. Semin Immunol. 2023;66:101727. https://doi.org/10.1016/j.smim.2023.101727

Vaughan K, Xu X, Caron E, Peters B, Sette A. Deciphering the MHC-associated peptidome: a review of naturally processed ligand data. Expert Rev Proteomics. 2017;14:729–36. https://doi.org/10.1080/14789450.2017.1361825

Nyambura LW, Jarmalavicius S, Baleeiro RB. Diverse HLA-I Peptide Repertoires of the APC Lines MUTZ3-Derived Immature and Mature Dendritic Cells and THP1-Derived Macrophages. The Journal of Immunology. 2016;197:2102–9. https://doi.org/10.4049/jimmunol.1600762

Demine R, Walden P. Sequit: software for de novo peptide sequencing by matrix-assisted laser desorption/ionization post-source decay mass spectrometry. Rapid Commun Mass Spectrom RCM. England; 2004;18:907–13. https://doi.org/10.1002/rcm.1420

UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. England; 2023;51:D523–31. https://doi.org/10.1093/nar/gkac1052

Mishra GR, Suresh M, Kumaran K, Kannabiran N, Suresh S, Bala P, et al. Human protein reference database--2006 update. Nucleic Acids Res. 2006;34:D411-4. https://doi.org/10.1093/nar/gkj141

Sondka Z, Dhir NB, Carvalho-Silva D. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Research. 2024;52:D1210-d1217. https://doi.org/10.1093/nar/gkad986

Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. England; 2019;47:D339–43. https://doi.org/10.1093/nar/gky1006

Gonzalez-Galarza FF, McCabe A, Santos E, Jones J, Takeshita L, Ortega-Rivera ND, et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 2020;48:D783-d788. https://doi.org/10.1093/nar/gkz1029

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinforma. United States; 2016;54:1.30.1-1.30.33. https://doi.org/10.1002/cpbi.5

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. England; 2019;47:D607–13. https://doi.org/10.1093/nar/gky1131

Jarmalavicius S, Welte Y, Walden P. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells. J Biol Chem. 2012;287:33401–11. https://doi.org/10.1074/jbc.M112.358903

Pritchard AL, Hastie ML, Neller M, Gorman JJ, Schmidt CW, Hayward NK. Exploration of peptides bound to MHC class I molecules in melanoma. Pigment Cell Melanoma Res. 2015;28:281–94. https://doi.org/10.1111/pcmr.12357

Schellens IM, Hoof I, Meiring HD, Spijkers SN, Poelen MC, van Gaans-van den Brink JA, et al. Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome. PLoS One. 2015;10:e0136417. https://doi.org/10.1371/journal.pone.0136417

Fissolo N, Haag S, de Graaf KL, Drews O, Stevanovic S, Rammensee HG, et al. Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients. Mol Cell Proteomics. 2009;8:2090–101. https://doi.org/10.1074/mcp.M900001-MCP200

Brito Baleeiro R, Liu P, Chard Dunmall LS, Di Gioia C, Nagano A, Cutmore L. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 2023;11:e007336. https://doi.org/10.1136/jitc-2023-007336

Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics. 2015;14:658–73. https://doi.org/10.1074/mcp.M114.042812

Rock KL, Farfán-Arribas DJ, Colbert JD, Goldberg AL. Re-examining class-I presentation and the DRiP hypothesis. Trends Immunol. 2014;35:144–52. https://doi.org/10.1016/j.it.2014.01.002

Abedin SA, Thorne JL, Battaglia S, Maguire O, Hornung LB, Doherty AP, et al. Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis. 2009;30:449–56. https://doi.org/10.1093/carcin/bgp005

Fozzatti L, Park JW, Zhao L, Willingham MC, Cheng SY. Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. PLoS One. 2013;8:e67954. https://doi.org/10.1371/journal.pone.0067954

Kim H, Park SH. TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer. Cancers. 2021;13(11):2601. https://doi.org/10.3390/cancers13112601

Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, et al. NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Lett. 2006;237:123–9. https://doi.org/ 10.1016/j.canlet.2005.05.046

Shu S, Li Z, Liu L, Ying X, Zhang Y, Wang T, et al. HPV16 E6-Activated OCT4 Promotes Cervical Cancer Progression by Suppressing p53 Expression via Co-Repressor NCOR1. Front Oncol. 2022;12:900856. https://doi.org/10.3389/fonc.2022.900856

St-Jean S, De Castro AC, Lecours M, Jones C, Rivard N, Rodier F. NCOR1 Sustains Colorectal Cancer Cell Growth and Protects against Cellular Senescence. Cancers. 2021;13(17):4414. https://doi.org/10.3390/cancers13174414

Tan J, Zhang S, Li L, Mu J, Wang Z, Zhang L, et al. Abnormally localized DLK1 interacts with NCOR1 in non-small cell lung cancer cell nuclear. Biosci Rep. 2019;39(12):BSR20192362. https://doi.org/10.1042/bsr20192362

Detilleux D, Raynaud P, Pradet-Balade B, Helmlinger D. The TRRAP transcription cofactor represses interferon-stimulated genes in colorectal cancer cells. Elife. 2022;11:e69705. https://doi.org/10.7554/eLife.69705

Kang KT, Kwon YW, Kim DK, Lee SI, Kim KH, Suh DS, et al. TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells. BMB Rep. 2018;51:514–9. https://doi.org/10.4048/jbc.2016.19.1.61

Kang KT, Shin MJ, Moon HJ, Choi KU, Suh DS. TRRAP Enhances Cancer Stem Cell Characteristics by Regulating NANOG Protein Stability in Colon Cancer Cells. International Journal of Molecular Sciences. 2023;24(7):6260. https://doi.org/10.3390/ijms24076260

Kwan SY, Sheel A, Song CQ, Zhang XO, Jiang T, Dang H, et al. Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes. Hepatology. 2020;71:275–90. https://doi.org/10.1002/hep.30807

Wang J, Shan M, Liu T, Shi Q, Zhong Z, Wei W, et al. Analysis of TRRAP as a Potential Molecular Marker and Therapeutic Target for Breast Cancer. J Breast Cancer 2016;19:61–7. https://doi.org/10.4048/jbc.2016.19.1.61

Jiang Y, Li T. Morphine in Combination with Ketamine Improves Cervical Cancer Pain and Suppresses Immune Function via the JAK3/STAT5 Pathway. Journal of Healthcare Engineering. 2022;2022:9364365. https://doi.org/10.1155/2022/9364365

Jin J, Guo Q, Xie J, Jin D, Zhu Y. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer. Pathol Oncol Res. 2019;25:769–75. https://doi.org/10.1007/s12253-019-00592-6

Li SD, Ma M, Li H, Waluszko A, Sidorenko T, Schadt EE, et al. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Med. 2017;9:89. https://doi.org/ 10.1186/s13073-017-0478-1

Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, et al. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015;3:855–63. https://doi.org/10.1158/2326-6066.cir-15-0024

Wu T, Yu J, Wang C, Jin Y, Zheng X, Chen L, et al. Novel Potent EGFR-JAK3 Dual-Target Inhibitor that Overcomes KRAS Mutation Resistance in Colorectal Cancer. Anticancer Agents Med Chem. 2023;23(4):440–9. https://doi.org/10.2174/1871520622666220609112816

Zhou C, Chen L, Chen R, Xu F, Huang Z, Huang R, et al. miR-4486 enhances cisplatin sensitivity of gastric cancer cells by restraining the JAK3/STAT3 signalling pathway. J Chemother. 2022;34:35–44. https://doi.org/ 10.1080/1120009x.2021.1936957

Canale M, Andrikou K, Priano I, Cravero P, Pasini L, Urbini M. The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. Cancers (Basel) 2022;14(5):1143. https://doi.org/10.3390/cancers14051143

Chen J, Chang X, Li X, Liu J, Wang N, Wu Y, et al. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations. Cancer Medicine. 2023;12:21920–32. https://doi.org/10.1002/cam4.6766

Liu B, Yi Z, Guan Y, Ouyang Q, Li C, Guan X, et al. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. Cancer Medicine. 2022;11(14):2767–78. https://doi.org/ 10.1002/cam4.4652

Liu J, Gao J. Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients. Eur J Cancer Prev. 2023;32:590–9. https://doi.org/10.1097/cej.0000000000000799

Michikawa C, Torres-Saavedra PA, Silver NL, Harari PM, Kies MS, Rosenthal DI, et al. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Advances in Radiation Oncology. 2022;7(6):100989. https://doi.org/ 10.1016/j.adro.2022.100989

Roeper J, Christopoulos P, Falk M, Heukamp LC, Tiemann M, Stenzinger A, et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res. 2022;11:4–13. https://doi.org/10.21037/tlcr-21-754

Sun H, Ren P, Chen Y, Lan L, Yan Z, Yang Y, et al. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study. BMC Cancer. 2023;23:198. https://doi.org/ 10.1186/s12885-023-10637-4

Abdelhamid D, Abdel-Aziz M, Li X, Jiang W, Dong S, Li W, et al. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules 2022;12(10):1450. https://doi.org/10.3390/biom12101450

Allam A, Yakou M, Pang L, Ernst M, Huynh J. Exploiting the STAT3 Nexus in Cancer-Associated Fibroblasts to Improve Cancer Therapy. Front Immunol. 2021;12:767939. https://doi.org/10.3389/fimmu.2021.767939

Dong J, Cheng XD, Zhang WD, Qin JJ. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. Journal of Medicinal Chemistry. 2021;64(13):8884–8915. https://doi.org/10.1021/acs.jmedchem.1c00629